SCHEMBL2350342

SCHEMBL2350342

CCCc1nnc(OC2CCN(C(=O)OC(C)(C)C)CC2)cc1-c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 9/20 0.51
YAP1 P46937 3/20 0.48
CACNB4 O00305 2/20 0.46
CACNA1A O00555 2/20 0.46
CACNA1G O43497 2/20 0.46
CACNG3 O60359 2/20 0.46
CACNA1F O60840 2/20 0.46
CACNA1H O95180 2/20 0.46
CACNB3 P54284 2/20 0.46
CACNA2D1 P54289 2/20 0.46
CACNG7 P62955 2/20 0.46
CACNA1B Q00975 2/20 0.46
CACNA1D Q01668 2/20 0.46
CACNB1 Q02641 2/20 0.46
CACNG1 Q06432 2/20 0.46
CACNB2 Q08289 2/20 0.46
CACNA1S Q13698 2/20 0.46
CACNA1C Q13936 2/20 0.46
CACNA1E Q15878 2/20 0.46
CACNA2D4 Q7Z3S7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2348312 0.95 PRMT5 (0.50) PRMT5YAP1CACNB4CACNA1ACACNA1G
SCHEMBL2348493 0.86 PRMT5 (0.52) PRMT5YAP1CACNB4CACNA1ACACNA1G
SCHEMBL2347727 0.85 YAP1 (0.50) PRMT5YAP1GPR119
SCHEMBL2347314 0.85 PRMT5 (0.43) PRMT5
SCHEMBL2352205 0.84 PDE4D (0.49) PRMT5YAP1CACNB4CACNA1ACACNA1G
Hydrochloric Acid SCHEMBL2352013 0.84 PRMT5 (0.43) PRMT5
SCHEMBL2352160 0.82 YAP1 (0.48) PRMT5YAP1GPR119
SCHEMBL2351993 0.81 CHEK2 (0.45) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL2353881 0.81 PRMT5 (0.43) PRMT5YAP1GPR119
SCHEMBL2348741 0.80 YAP1 (0.42) PRMT5YAP1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2536283-B1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA LLC (US) 2015-07-29 EP disclosed
US-9045461-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, LLC (US) 2015-06-02 US disclosed
US-20140206660-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof TRANSTECH PHARMA, LLC (US) 2014-07-24 US disclosed
US-8741900-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, LLC (US) 2014-06-03 US disclosed
US-20130197007-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof TRANSTECH PHARMA, INC. (US) 2013-08-01 US disclosed
US-8431575-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, INC. (US) 2013-04-30 US disclosed
EP-2536283-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TransTech Pharma, Inc (US) 2012-12-26 EP disclosed
US-20110230458-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA, INC. (US) 2011-09-22 US disclosed
WO-2011103091-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA, INC. (US) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206660-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof AGER, NOD2, GPBAR1 PRMT5 2427/4885YAP1 2128/4885CACNB4 4084/4885
US-20110230458-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF AGER, PSEN2, PSEN1 PRMT5 1779/4885YAP1 1433/4885CACNB4 3517/4885
US-20130197007-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof AGER, PSEN2, PSEN1 PRMT5 1779/4885YAP1 1433/4885CACNB4 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.